Congress trades
Intellia Therapeutics, Inc. (NTLA)
Free on iOS and Android.
About Intellia Therapeutics, Inc.
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- John Leonard
- Employees
- 377
- Listed since
- May 6, 2016
- Market value
- $1.6B
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$3.00
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 5, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 6, 2026 | -$0.80 | -$0.80 | $7.7M | $13.0M | EPS in line, GAAPRevenue miss |
| Q1 FY2026reported May 11, 2026 | -$0.81 | -$0.92 | $15.0M | $13.8M | EPS beat, GAAPRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | -$0.83 | -$0.99 | $23.0M | $12.0M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 6, 2025 | -$0.92 | -$1.02 | $13.8M | $12.2M | EPS beat, GAAPRevenue beat |
| Q2 FY2025reported Aug 7, 2025 | -$0.99 | -$1.03 | $14.2M | $14.1M | EPS beat, GAAPRevenue in line |
| Q1 FY2025reported May 8, 2025 | -$1.10 | -$1.26 | $16.6M | $11.9M | EPS beat, GAAPRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 30, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| John M. Leonard, M.D.President, Chief Executive Officer | $708K | $2.4M | $1.9M | $5.1M |
| Edward J. Dulac IIIExecutive Vice President, Chief Financial Officer and Treasurer | $526K | $848K | $794K | $2.2M |
| David Lebwohl, M.D.Executive Vice President, Chief Medical Officer | $536K | $776K | $672K | $2.0M |
| James Basta, J.D.Executive Vice President, General Counsel and Corporate Secretary | $494K | $719K | $634K | $1.8M |
| Birgit Schultes, Ph.D.Executive Vice President, Chief Scientific Officer | $475K | $676K | $589K | $1.7M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| ARK Investment Management LLCCathie Wood | $285.5M | 16,875,684 | +16.3% | 12.64% |
| BlackRock, Inc. | $260.7M | 15,409,023 | +26.8% | 11.54% |
| State Street Corp | $156.3M | 9,234,987 | +33.4% | 6.92% |
| Vanguard Portfolio Management LLC | $124.1M | 7,332,401 | +17.8% | 5.49% |
| D. E. Shaw & Co., Inc. | $109.0M | 6,443,323 | +12.5% | 4.83% |
| Vanguard Capital Management LLC | $102.0M | 6,028,586 | +18.6% | 4.52% |
| Two Sigma Investments, LP | $88.6M | 5,235,348 | +11.3% | 3.92% |
| FMR LLC | $80.8M | 4,773,034 | +130.9% | 3.58% |
| RA Capital Management, L.P. | $76.6M | 4,526,926 | New | 3.39% |
| Regeneron Pharmaceuticals, Inc. | $62.7M | 3,702,995 | 0.0% | 2.77% |
| Geode Capital Management, LLC | $61.4M | 3,631,061 | +27.3% | 2.72% |
| Arrowstreet Capital, Limited Partnership | $55.5M | 3,280,760 | +134.8% | 2.46% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding NTLA
2 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Cathie WoodARK Invest | $285.5M | 16,875,684 | 1.9% |
| RA Capital ManagementPeter Kolchinsky | $76.6M | 4,526,926 | 0.7% |
2 of the 97 fund managers we track list NTLA shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in NTLA
10 disclosures of 10 on record · median 12d of the 45 allowedSince the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Donald S. Beyer, Jr.Joint | Stock | Sale | $15,001 - $50,000 | n/a | Feb 28, 2022 | Mar 3, 2022 | 3d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | n/a | Oct 29, 2021 | Oct 30, 2021 | 1d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | n/a | Sep 20, 2021 | Oct 1, 2021 | 11d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | n/a | Jul 21, 2021 | Aug 7, 2021 | 17d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | n/a | Jan 15, 2021 | Jan 31, 2021 | 16d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | n/a | Nov 18, 2020 | Dec 1, 2020 | 13d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | n/a | Aug 26, 2020 | Sep 6, 2020 | 11d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | n/a | Jul 10, 2020 | Aug 9, 2020 | 30d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | n/a | Jan 14, 2020 | Feb 22, 2020 | 39d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | n/a | Dec 9, 2019 | Dec 14, 2019 | 5d |
We hold no closing prices for any row shown here, so no move is shown. Not investment advice.
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in NTLA, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded NTLA?
Donald S. Beyer, Jr. disclosed NTLA transactions in the filings shown here.
How quickly are NTLA trades disclosed?
Congressional disclosures took a median of 12 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 27, 2026.